Fong Clow
Corporate Officer/Principal bei SUMMIT THERAPEUTICS INC.
Aktive Positionen von Fong Clow
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 16.10.2023 | - |
Karriereverlauf von Fong Clow
Ehemalige bekannte Positionen von Fong Clow
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Corporate Officer/Principal | 01.03.2005 | 03.02.2009 |
ABBVIE INC. | Corporate Officer/Principal | - | - |
PHARMACYCLICS, INC. | Corporate Officer/Principal | 01.04.2011 | - |
Ausbildung von Fong Clow
Wuhan University | Undergraduate Degree |
Harvard T.H. Chan School of Public Health | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
China | 2 |
Operativ
Corporate Officer/Principal | 4 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SUMMIT THERAPEUTICS INC. | Health Technology |
ABBVIE INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |